Desmopressin in moderate hemophilia A patients: a treatment worth considering.

Desmopressin in moderate hemophilia A patients: a treatment worth considering. Haematologica. 2018 Jan 05;: Authors: Loomans JI, Kruip MJHA, Carcao M, Jackson S, van Velzen AS, Peters M, Santagostino E, Platokouki H, Beckers E, Voorberg J, van der Bom JG, Fijnvandraat K Abstract Desmopressin increases endogenous factor VIII levels in hemophilia A. Large inter-individual variation in the response to desmopressin is observed. Patients with a lower baseline factor VIII activity tend to show a reduced response. Therefore, desmopressin is less frequently used in moderate hemophilia A patients (baseline factor VIII activity 1-5 international units/deciliter), even though factor VIII levels may rise substantially in some of them. We aim to describe the response to desmopressin in moderate hemophilia A patients and to identify predictors. We selected data on 169 patients with moderate hemophilia from the multicenter RISE cohort study. Adequate response to desmopressin was defined as a peak factor VIII level ≥ 30 and excellent response as ≥ 50 international units/deciliter after desmopressin administration. We used univariate and multiple linear regression techniques to analyze predictors of the peak factor VIII level. Response was considered adequate in 68 patients (40%), of whom 25 showed excellent response (15%). Intravenous administration, age, pre-desmopressin factor VIII activity and Von Willebrand factor antigen, peak Von Willebran...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research